Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.

Autor: Sakagami M; Department of Radiation Oncology, Graduate School of Medicine, Osaka City University, Osaka, Japan. o21064c@omu.ac.jp., Inokuchi H; Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Mukumoto N; Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Itoyama H; Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Hamaura N; Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Yamagishi M; Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Mukumoto N; Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Matsuda S; Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Kabata D; Department of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Shibuya K; Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Jazyk: angličtina
Zdroj: Radiation oncology (London, England) [Radiat Oncol] 2023 May 22; Vol. 18 (1), pp. 87. Date of Electronic Publication: 2023 May 22.
DOI: 10.1186/s13014-023-02276-7
Abstrakt: Background: The current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) combined with durvalumab consolidation therapy. However, radiotherapy (RT) always carries the risk of radiation pneumonitis (RP), which can preclude durvalumab continuation. In particular, the spread of interstitial lung disease (ILD) in low-dose areas or extending beyond the RT field often makes it difficult to determine the safety of continuation or rechallenging of durvalumab. Thus, we retrospectively analyzed ILD/RP after definitive RT with and without durvalumab, with assessment of radiologic features and dose distribution in RT.
Methods: We retrospectively evaluated the clinical records, CT imaging, and radiotherapy planning data of 74 patients with NSCLC who underwent definitive RT at our institution between July 2016 and July 2020. We assessed the risk factors for recurrence within one year and occurrence of ILD/RP.
Results: Kaplan-Meier method showed that ≥ 7 cycles of durvalumab significantly improved 1-year progression free survival (PFS) (p < 0.001). Nineteen patients (26%) were diagnosed with ≥ Grade 2 and 7 (9.5%) with ≥ Grade 3 ILD/RP after completing RT. There was no significant correlation between durvalumab administration and ≥ Grade 2 ILD/RP. Twelve patients (16%) developed ILD/RP that spread outside the high-dose (> 40 Gy) area, of whom 8 (67%) had ≥ Grade 2 and 3 (25%) had Grade 3 symptoms. In unadjusted and multivariate Cox proportional-hazards models adjusted for V 20 (proportion of the lung volume receiving ≥ 20 Gy), high HbA1c level was significantly correlated with ILD/RP pattern spreading outside the high-dose area (hazard ratio, 1.842; 95% confidence interval, 1.35-2.51).
Conclusions: Durvalumab improved 1-year PFS without increasing the risk of ILD/RP. Diabetic factors were associated with ILD/RP distribution pattern spreading in the lower dose area or outside RT fields, with a high rate of symptoms. Further study of the clinical background of patients including diabetes is needed to safely increase the number of durvalumab doses after CRT.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje